FDA, Insulin and Biosimilar
FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes
Agency Continues Efforts to Increase Access to Insulin Treatment Options SILVER SPRING, Md., /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus.
More than 36 million Americans have type 2 diabetes, a condition primarily attributed to the body's cells not responding to ...
People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With ...
Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...
If insulin can’t get out of blood vessels, it can’t act in its target tissues. “Endothelial cells are full of insulin ...
People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With open-loop therapies, insulin administration is manually controlled, while hybrid ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback